
Last updated: 15 November 2026 | Author: Prashant Tyagi (Stem Cell Biotechnology Specialist, 10+ years) and Dr. Pallavee Senior Consultant | Ophthalmologist & Eye Surgeon 22+ Years Experience
Learning that a baby or young child has Leber congenital amaurosis (LCA) is overwhelming. It is a rare inherited retinal disease that causes severe vision loss from very early life. Families often search for stem cell therapy hoping for a way to restore sight. This guide gives you the honest picture: what LCA is, why genetic testing is the most important step, what gene therapy exists for one form, where stem cell therapy stands and how to support your child now.
Quick Navigation
LCA is a group of inherited retinal dystrophies that cause severe visual impairment at birth or in the first months of life. The retina, especially the light-sensing cells, does not work properly. It is related to retinitis pigmentosa but usually starts much earlier and more severely. Several genes can cause LCA, and the exact gene decides the outlook and the options. See also the condition page on LCA at retinitis-pigmentosa.co.in.
Any baby who does not seem to see should be seen by a paediatric ophthalmologist promptly. Other conditions can look similar, including problems of the optic nerve and brain, and the right diagnosis matters.
| Test | Purpose |
|---|---|
| Paediatric eye examination | Looks at the eyes, pupils and retina |
| Electroretinogram (ERG) | Shows how the retina responds to light; usually very reduced or absent in LCA |
| Visual evoked potential (VEP) | Measures signals from eye to brain |
| OCT (where age and cooperation allow) | Shows retinal structure |
| Genetic testing | Finds the gene involved; the most important test for options and counselling |
| MRI or other tests if needed | Rule out brain or optic nerve causes and look for other conditions |
Genetic testing in LCA is important because it can show whether your child has changes in the RPE65 gene, for which an approved gene therapy exists, and because it guides counselling for the family.
A gene therapy called voretigene neparvovec has been approved in several countries for people with inherited retinal disease caused by changes in both copies of the RPE65 gene. It is given by injection under the retina by specialised surgeons. It applies only to this specific genetic group, which is a small portion of people with LCA. Availability, eligibility, cost and access in India differ, so ask a retina or genetics specialist whether your child’s result qualifies and where it can be accessed. Research on other LCA genes is active, and some experimental approaches are in trials. Check registered trials at the Clinical Trials Registry – India and on international registries.
Stem cell therapy is not an approved treatment for LCA, and it is not a cure. Studies of cell-based approaches for inherited retinal disease are early, mostly experimental and cannot replace the specific gene function that is missing in LCA. Results from clinics that offer stem cell injections vary, and there are documented cases of harm after unregulated eye injections in other conditions. In young children, procedures may also need anaesthesia, which has its own risks. Families should be told clearly that any use is investigational, that benefit is uncertain, and that written consent will be taken. The independent patient resource from the ISSCR (linked below) is worth reading before any decision. Our own approach is described on our stem cell therapy in India page, and we will say plainly if your reports suggest it is unlikely to help.
LCA is usually inherited in a recessive pattern. This means both parents typically carry a changed copy of the gene without having symptoms. Each pregnancy of the same parents has a chance of an affected child. Genetic counselling explains your family’s risk and options, including testing in future pregnancies if you wish.
No. Stem cell therapy is not an approved or proven treatment for LCA. Research is at an early stage.
A gene therapy is approved for LCA or related disease caused by RPE65 changes, in countries where it is available. Most other genetic forms have no approved therapy yet.
It identifies the gene, which decides eligibility for gene therapy and trials, and supports family counselling.
The level of vision varies. Some children have some light or shape perception. Your specialist can assess your child.
Ask your doctor about early intervention and parent groups, and read about related conditions such as rod and cone dystrophy. You can also use the contact page.

